InvestorsHub Logo

DCorleone

09/28/17 1:53 PM

#62027 RE: Spider Web #62026

RXMD Comparison... Year 2017 Versus 2016 Month, Quarterly

1/2016 1.3... 1/2017 1.6
2/2016 1.1... 2/2017 1.5
3/2016 1.5... 3/2017 1.6

Total 3.9...2016... 4.7... 2017

4/2016 1.4... 4/2017 1.4
5/2016 1.4... 5/2017 1.9
6/2016 1.7... 6/2017 1.7

Total 4.5...2016... 5.0...2017

7/2016 1.5.... 7/2017 1.7
8/2016 1.75... 8/2017 1.8
9/2016 1.6....

10/2016 1.6
11/2016 1.7
12/2016 1.7

gedi8

09/28/17 2:34 PM

#62029 RE: Spider Web #62026

It surely isn't you

Wangenstein

09/28/17 2:36 PM

#62030 RE: Spider Web #62026

Only if you enjoy poorly written fiction...

Spider Web

09/29/17 12:00 PM

#62055 RE: Spider Web #62026

MORE TROUBLE AHEAD


INCREDIBLY OVERVALUED

YES SIR . . .

BAD THINGS HAVE COME TO
THOSE THAT HAVE WAITED



The Company Will Not Up-Grade To The OTC-QB Next Month. Even If They Fill Out A Form, It Will Still Take Much Longer Before The Eventual Rejection. Especially If The SP Sinks Below The Currently Dangerous "One Cent" Level.

This Will Render It All Worthless As The Company Starts A Dilution Process, Followed By The Impending Reverse-Split. That's The Big Fear. That's Why There Will Be A Story-Line Attempt To Pump-Up The PPS, To Try And Keep It Above "One Cent".


IF INVESTORS WAIT A FEW WEEKS, THEY WILL MOST LIKELY BE ABLE TO BUY AT A LOWER RISK LEVEL AROUND THE $0.005 TRIPLE BOTTOM. HOWEVER, FURTHER RISK WILL STILL EXIST.

BE VERY WEARY OF ANY THIRD PARTY IR BLOG ARTICLE THAT MAY BE TRYING TO INDUCE SOMETHING THAT IS NOWHERE NEAR ANYTHING THAT MAY BE CLAIMED

There Will Be No MA Completed By The EOY Either. That Is Just A Pump Oriented Story-Line. Any JV Or MA At This Time Will Further Drive This Company Into Even More Contraction, Instead Of Any Growth. Thus Ruining Any Chances Of Staying Out Of Debt.

The Growth Run Of Almost Two Years Ago Has Already Happened. And Any Further Potential Revenue Or Prescription-Unit Growth Has Already Topped-Out, And Is Well Into The Midst's Of A Contraction.


ANY STORY-LINE OR BLOG ARTICLE BEING EXAGGERATED AT THIS POINT IN TIME IS SOLELY FOR THE CURRENT DANGER OF THE PPS FALLING BELOW THE ONE CENT LEVEL . . . P E R I O D

The Company Is Nowhere Near The Previously Touted Revenue Projections Of $22M For The Fiscal Year Of 2017. Another Lofty Goal Of Achieving 25K Prescription-Units In A Single Month This Year, Which Strung-Out Investors For Over A Year, Will Also NOT Be Achieved Anytime Soon !!! ... Beware: The Net Income / Loss And The Amount Of Available Cash Is Also Nowhere Near To Being In-Line With Revenues.

NOWHERE NEAR ON ALL FRONTS

Data Just Shows The Opposite
GROWTH HAS STOPPED
* NOW CONTRACTION *


There Will Be No Up-List To The NASDAQ In 2018 As Well. That Is A Totally Irresponsible, Premature, And Incorrect Assumption At This Time.


WHEN IN DOUBT -----> STAY OUT !!!